Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Yohannes W. Woldeamanuel is active.

Publication


Featured researches published by Yohannes W. Woldeamanuel.


Pain | 2014

Sensory, psychological, and metabolic dysfunction in HIV-associated peripheral neuropathy: A cross-sectional deep profiling study.

Tudor J.C. Phillips; Matthew Brown; Juan D. Ramirez; James R. Perkins; Yohannes W. Woldeamanuel; Amanda C. de C. Williams; Christine A. Orengo; David L. H. Bennett; Istvan Bodi; Sarah Cox; Christoph Maier; Elena K. Krumova; Andrew S.C. Rice

Summary Study participants with HIV‐associated sensory polyneuropathy (HIV‐SN) had higher plasma triglyceride concentrations, depression, anxiety, catastrophizing scores, and prevalence of insomnia than HIV participants without HIV‐SN. ABSTRACT HIV‐associated sensory neuropathy (HIV‐SN) is a frequent complication of HIV infection and a major source of morbidity. A cross‐sectional deep profiling study examining HIV‐SN was conducted in people living with HIV in a high resource setting using a battery of measures which included the following: parameters of pain and sensory symptoms (7 day pain diary, Neuropathic Pain Symptom Inventory [NPSI] and Brief Pain Inventory [BPI]), sensory innervation (structured neurological examination, quantitative sensory testing [QST] and intraepidermal nerve fibre density [IENFD]), psychological state (Pain Anxiety Symptoms Scale‐20 [PASS‐20], Depression Anxiety and Positive Outlook Scale [DAPOS], and Pain Catastrophizing Scale [PCS], insomnia (Insomnia Severity Index [ISI]), and quality of life (Short Form (36) Health Survey [SF‐36]). The diagnostic utility of the Brief Peripheral Neuropathy Screen (BPNS), Utah Early Neuropathy Scale (UENS), and Toronto Clinical Scoring System (TCSS) were evaluated. Thirty‐six healthy volunteers and 66 HIV infected participants were recruited. A novel triumvirate case definition for HIV‐SN was used that required 2 out of 3 of the following: 2 or more abnormal QST findings, reduced IENFD, and signs of a peripheral neuropathy on a structured neurological examination. Of those with HIV, 42% fulfilled the case definition for HIV‐SN (n = 28), of whom 75% (n = 21) reported pain. The most frequent QST abnormalities in HIV‐SN were loss of function in mechanical and vibration detection. Structured clinical examination was superior to QST or IENFD in HIV‐SN diagnosis. HIV‐SN participants had higher plasma triglyceride, concentrations depression, anxiety and catastrophizing scores, and prevalence of insomnia than HIV participants without HIV‐SN.


Cephalalgia | 2015

The place of corticosteroids in migraine attack management: A 65-year systematic review with pooled analysis and critical appraisal

Yohannes W. Woldeamanuel; Alan M. Rapoport; Robert P. Cowan

Background and objectives Headaches recur in up to 87% of migraine patients visiting the emergency department (ED), making ED recidivism a management challenge. We aimed herein to determine the role of corticosteroids in the acute management of migraine in the ED and outpatient care. Methods Advanced search strategies employing PubMed/MEDLINE, Web of Science, and Cochrane Library databases inclusive of a relevant gray literature search was employed for Clinical Studies and Systematic Reviews by combining the terms “migraine” and “corticosteroids” spanning all previous years since the production of synthetic corticosteroids ca. 1950 until August 30, 2014. Methods were in accordance with MOOSE guidelines. Results Twenty-five studies (n = 3989, median age 37.5 years, interquartile range or IQR 35–41 years; median male:female ratio 1:4.23, IQR 1:2.1–6.14; 52% ED-based, 56% randomized-controlled) and four systematic reviews were included. International Classification of Headache Disorders criteria were applied in 64%. Nineteen studies (76%) indicated observed outcome differences favoring benefits of corticosteroids, while six (24%) studies indicated non-inferior outcomes for corticosteroids. Median absolute risk reduction was 30% (range 6%–48.2%), and 11% (6%–48.6%) for 24-, and 72-hour headache recurrence, respectively. Parenteral dexamethasone was the most commonly (56%) administered steroid, at a median single dose of 10 mg (range 4–24 mg). All meta-analyses revealed efficacy of adjuvant corticosteroids to various abortive medications—indicating generalizability. Adverse effects were tolerable. Higher disability, status migrainosus, incomplete pain relief, and previous history of headache recurrence predicted outcome favorability. Conclusions Our literature review suggests that with corticosteroid treatment, recurrent headaches become milder than pretreated headaches and later respond to nonsteroidal therapy. Single-dose intravenous dexamethasone is a reasonable option for managing resistant, severe, or prolonged migraine attacks.


Journal of Neurology | 2012

Neurolathyrism: two Ethiopian case reports and review of the literature

Yohannes W. Woldeamanuel; Anhar Hassan; Guta Zenebe

Neurolathyrism is a toxic myelopathy caused by ingestion of the Lathyrus sativus grasspea. An irreversible acute to subacute spastic paraparesis or quadriparesis ensues. Despite public education, new cases of this preventable disease still occur. Two Ethiopian cases of neurolathyrism are reported to illustrate the disease, followed by a literature review. Two teenage male farmers from the same village developed irreversible spastic myelopathy following L. sativus ingestion. There was no sensory, sphincter or bulbar dysfunction. Likely causative factors identified were increased consumption of L. sativus prior to and following disease onset, heavy physical exertion and male gender, similar to those reported in the literature. Neurolathyrism is an entirely preventable neurotoxic myelopathy with permanent disability accrued. Treatment is symptomatic. Because of personal disability and subsequent socioeconomic effects, this disease warrants further public health measures to prevent occurrence. Education, avoidance of the grasspea and measures to reduce toxin burden are possible methods.


Lancet Oncology | 2013

Cancer in Ethiopia

Yohannes W. Woldeamanuel; Belaineh Girma; Alula M Teklu

Ethiopia has a population of more than 84 million people and is expected to become the ninth most populous country in the world by 2050. The growing population coupled with lifestyle changes will mean an increasing burden of cancer. However, oncology services are wholly inadequate--no cancer registry exists, and only one cancer centre, with a handful of doctors and nurses, struggles to serve the entire country.


PLOS ONE | 2016

Development, Validation, and Field-Testing of an Instrument for Clinical Assessment of HIV-Associated Neuropathy and Neuropathic Pain in Resource-Restricted and Large Population Study Settings

Yohannes W. Woldeamanuel; Peter R. Kamerman; Demetri G. A. Veliotes; Tudor J.C. Phillips; David Asboe; Marta Boffito; Andrew S.C. Rice

HIV-associated sensory peripheral neuropathy (HIV-SN) afflicts approximately 50% of patients on antiretroviral therapy, and is associated with significant neuropathic pain. Simple accurate diagnostic instruments are required for clinical research and daily practice in both high- and low-resource setting. A 4-item clinical tool (CHANT: Clinical HIV-associated Neuropathy Tool) assessing symptoms (pain and numbness) and signs (ankle reflexes and vibration sense) was developed by selecting and combining the most accurate measurands from a deep phenotyping study of HIV positive people (Pain In Neuropathy Study–HIV-PINS). CHANT was alpha-tested in silico against the HIV-PINS dataset and then clinically validated and field-tested in HIV-positive cohorts in London, UK and Johannesburg, South Africa. The Utah Early Neuropathy Score (UENS) was used as the reference standard in both settings. In a second step, neuropathic pain in the presence of HIV-SN was assessed using the Douleur Neuropathique en 4 Questions (DN4)-interview and a body map. CHANT achieved high accuracy on alpha-testing with sensitivity and specificity of 82% and 90%, respectively. In 30 patients in London, CHANT diagnosed 43.3% (13/30) HIV-SN (66.7% with neuropathic pain); sensitivity = 100%, specificity = 85%, and likelihood ratio = 6.7 versus UENS, internal consistency = 0.88 (Cronbach alpha), average item-total correlation = 0.73 (Spearman’s Rho), and inter-tester concordance > 0.93 (Spearman’s Rho). In 50 patients in Johannesburg, CHANT diagnosed 66% (33/50) HIV-SN (78.8% neuropathic pain); sensitivity = 74.4%, specificity = 85.7%, and likelihood ratio = 5.29 versus UENS. A positive CHANT score markedly increased of pre- to post-test clinical certainty of HIV-SN from 43% to 83% in London, and from 66% to 92% in Johannesburg. In conclusion, a combination of four easily and quickly assessed clinical items can be used to accurately diagnose HIV-SN. DN4-interview used in the context of bilateral feet pain can be used to identify those with neuropathic pain.


Headache | 2016

Indomethacin Responsive Headaches: Exhaustive Systematic Review with Pooled Analysis and Critical Appraisal of 81 Published Clinical Studies.

Emilia C. Bordini; Carlos A. Bordini; Yohannes W. Woldeamanuel; Alan M. Rapoport

The relationship between indomethacin (IMC) and headache treatment has long intrigued clinicians and clinical researchers in Headache Medicine. Why is it efficacious in many types of headache disorders when other medications are not, and what is the mechanism behind its efficacy? IMC and headache related topics that have been explored in detail in the literature include IMC‐responsive headache disorders (“traditional”), pharmacology of IMC, symptomatic headaches responsive to IMC, “novel” headache conditions that respond, cluster headache and IMC, IMC provoking headache, the issue about” absolute” and “non‐absolute” effect of IMC on headache disorders, and the morphing trigeminal autonomic cephalalgias (TACs).


Current Pain and Headache Reports | 2017

Headache in Resource-Limited Settings

Yohannes W. Woldeamanuel

Purpose of ReviewThis review summarizes the unmet need of headache burden and management in resource-limited settings. It provides a general overview of the nuances and peculiarities of headache disorders in resource-limited settings. The review delivers perspectives and explanations for the emerging burden of both primary and secondary headache disorders. Important discussion on demographic and epidemiologic transition pertinent to low-resource settings is included. A critical analysis of headache disorders is made within the context of growing burden non-communicable disorders in low-resource countries. Challenges are examined and prospective feasible solutions tailored to existing resources are provided to address headache disorders in resource-limited settings.Recent FindingsMany low-resource countries are entering into the third epidemiological transition featuring increasing burden of non-communicable disorders of which headache disorders contribute a significant proportion. Exponential population growth involving youthful demographic and massive rural-urban migration is taking place in low-resource countries. Youthful demographic is the natural cohort for primary headache such as migraine. Socioeconomic mobility and lifestyle changes are leading to higher levels of physical inactivity and obesity, both of which are related to headache. Life expectancy is rising in some resource-restricted countries; this increases prevalence of secondary headache attributed to neurovascular causes. Many low-resource countries are still burdened with tropical infectious causes of secondary headache. Health care facilities are primarily designed to respond to infectious epidemic and not to chronic burden such as headache. Many low-resource-restricted settings are plagued by poor and corrupt governance, ill-equipped regimes with malfunctioning health policies, war, and poverty. Many low-resource settings do not have access to generic headache medications such as triptans. Headache training and expertise is low. Healthy lifestyle changes emphasizing on improving regular exercise can be inexpensive method to reducing primary headache burden and its comorbidities (e.g. obesity).SummaryAddressing the increasing burden of headache disorders in resource-limited settings is important to avert accrued disability which in turn lowers productivity and socioeconomic performance in a young booming population.


Neurology | 2016

Journal Club: Exacerbation of headache during dihydroergotamine for chronic migraine does not alter outcome

Yohannes W. Woldeamanuel; Meabh O'Hare; Danielle D. DeSouza; Robert P. Cowan

Transient headache exacerbation during IV dihydroergotamine (DHE) therapy of migraine may prompt clinicians to prematurely discontinue DHE therapy, potentially depriving patients of the full benefit of DHE infusion. In a recent Neurology® article, Eller et al. evaluated whether or not worsening headache during DHE infusion was associated with suboptimal medium-term headache outcomes.


Neurology | 2016

Journal Club: Change in brain network connectivity during PACAP38-induced migraine attacks

Danielle D. DeSouza; Meabh O'Hare; Yohannes W. Woldeamanuel; Robert P. Cowan

There is evidence to suggest that migraine attacks involve changes in complex neuronal networks that can be measured using functional MRI (fMRI) methods including resting state functional connectivity (RSFC). Networks that have previously been shown to be involved in the sensory and affective aspects of pain perception include the default mode network (DMN), salience network (SN), and sensorimotor network (SMN) (figure).1 In a recent study, Amin et al.2 examined the RSFC of these 3 networks at baseline and in the early phases of experimentally induced migraine in patients with migraine without aura. In order to capture the early phases of migraine, corresponding to the time closest to migraine attack onset, migraine attacks were induced using the potent vasodilator neuropeptide pituitary adenylate cyclase-activating polypeptide-38 (PACAP38).3 Since vasodilators can alter hemodynamics and potentially confound the fMRI signal, another vasodilator, vasoactive intestinal peptide (VIP), was used as a control since it also acts on extracranial arteries, but is much less likely (<20%) to provoke migraine-like attacks.3


Cephalalgia | 2016

Spontaneous extracranial hemorrhagic phenomena in primary headache disorders: A systematic review of published cases.

Addie Peretz; Yohannes W. Woldeamanuel; Alan M. Rapoport; Robert P. Cowan

Background Head pain is a cardinal feature of primary headache disorders (PHDs) and is often accompanied by autonomic and vasomotor symptoms and/or signs. Spontaneous extracranial hemorrhagic phenomena (SEHP), including epistaxis, ecchymosis, and hematohidrosis (a disorder of bleeding through sweat glands), are poorly characterized features of PHDs. Aim To critically appraise the association between SEHP and PHDs by systematically reviewing and pooling all reports of SEHP associated with headaches. Methods Advanced searches using the PubMed/MEDLINE, Web of Science, Cochrane Library, Google Scholar, and ResearchGate databases were carried out for clinical studies by combining the terms “headache AND ecchymosis”, “headache AND epistaxis”, and “headache AND hematohidrosis” spanning all medical literature prior to October 10, 2015. Preferred Reporting Items for Systematic Reviews and Meta-analyses and Meta-analysis of Observational Studies in Epidemiology guidelines were applied. Results A total of 105 cases of SEHP associated with PHDs (83% migraine and 17% trigeminal autonomic cephalgias) were identified (median age 27 years, male to female ratio 1:2.3); 63% had epistaxis, 33% ecchymosis, and 4% hematohidrosis. Eighty-three percent of studies applied the International Classification of Headache Disorders diagnostic criteria. Eighty percent of the reported headaches were episodic and 20% were chronic. Twenty-four percent of studies reported recurrent episodes of SEHP. Conclusions Our results suggest that SEHP may be rare features of PHDs. Future studies would benefit from the systematic characterization of these phenomena.

Collaboration


Dive into the Yohannes W. Woldeamanuel's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Guta Zenebe

Addis Ababa University

View shared research outputs
Researchain Logo
Decentralizing Knowledge